VRTX Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 0.20%

Insider Buying (Last 12 Months): $1,948,400.00

Insider Selling (Last 12 Months): $118,095,407.99

Vertex Pharmaceuticals Insider Trading History Chart

Vertex Pharmaceuticals Share Price & Price History

^$451.63

+0.30 (1.20%)

As of 06/18/2026 04:00 PM ET

Days: 30 | 90 | 365

Vertex Pharmaceuticals Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/15/2026	Carmen Bozic	CMO	Sell	4,062	$450.00	$1,827,900.00	16,953
6/5/2026	Carmen Bozic	CMO	Sell	1,745	$450.00	$785,250.00	21,015
5/12/2026	Carmen Bozic	CMO	Sell	6,988	$450.00	$3,144,600.00	26,088
5/4/2026	Sangeeta N Bhatia	Director	Sell	318	$423.73	$134,746.14	4,924
5/1/2026	Joy Liu	EVP	Sell	1,104	$425.02	$469,222.08	20,729
4/1/2026	Joy Liu	EVP	Sell	978	$449.17	$439,288.26	21,833
3/13/2026	Carmen Bozic	CMO	Sell	2,329	$481.79	$1,122,088.91	35,405
2/25/2026	Amit Sachdev	EVP	Sell	1,846	$486.35	$897,802.10	55,570
2/25/2026	Duncan McKechnie	EVP	Sell	4,910	$487.65	$2,394,361.50	17,559
2/25/2026	E. Morrey Atkinson, III	EVP	Sell	668	$486.35	$324,881.80	18,432
2/25/2026	Jonathan Biller	EVP	Sell	945	$486.35	$459,600.75	13,659
2/25/2026	Kristen Ambrose	CAO	Sell	223	$486.35	$108,456.05	6,981
2/25/2026	Mark E. Bunnage	EVP	Sell	620	$486.35	$301,537.00	7,284
2/25/2026	Ourania Tatsis	EVP	Sell	260	$486.35	$126,451.00	46,763
2/19/2026	Amit Sachdev	EVP	Sell	58,613	$468.83	$27,479,532.79	58,934
2/13/2026	Ourania Tatsis	EVP	Sell	1,500	$499.99	$749,985.00	46,132
2/11/2026	E. Morrey Atkinson, III	EVP	Sell	1,751	$460.43	$806,212.93	22,046
2/11/2026	Jonathan Biller	EVP	Sell	1,925	$460.43	$886,327.75	20,819
2/11/2026	Kristen Ambrose	CAO	Sell	1,376	$460.43	$633,551.68	10,127
2/11/2026	Mark E. Bunnage	EVP	Sell	2,021	$460.43	$930,529.03	12,914
2/11/2026	Ourania Tatsis	EVP	Sell	466	$460.43	$214,560.38	51,436
1/7/2026	Ourania Tatsis	EVP	Sell	4,500	$474.99	$2,137,455.00	42,293
1/6/2026	Charles F. Wagner, Jr.	EVP	Sell	9,532	$461.00	$4,394,252.00	37,725
12/3/2025	Charles F. Wagner, Jr.	EVP	Sell	14,000	$456.00	$6,384,000.00	37,725
12/3/2025	Jeffrey M. Leiden	Chairman	Sell	63,781	$449.20	$28,650,425.20	24,026
11/14/2025	Jeffrey M. Leiden	Chairman	Sell	53,604	$440.72	$23,624,354.88	24,026
11/13/2025	Jeffrey M. Leiden	Chairman	Sell	19,688	$440.27	$8,668,035.76	24,026
8/6/2025	Bruce I. Sachs	Director	Buy	5,000	$389.68	$1,948,400.00	45,000
5/15/2025	David Altshuler	EVP	Sell	52	$424.69	$22,083.88	23,281
3/10/2025	David Altshuler	EVP	Sell	3,231	$500.00	$1,615,500.00	26,512
2/27/2025	Ourania Tatsis	EVP	Sell	530	$475.34	$251,930.20	58,539
2/18/2025	Ourania Tatsis	EVP	Sell	244	$455.06	$111,034.64	67,695
2/11/2025	Ourania Tatsis	EVP	Sell	310	$459.83	$142,547.30	64,021
11/15/2024	David Altshuler	EVP	Sell	15	$478.56	$7,178.40	25,813
8/30/2024	Jeffrey M. Leiden	Chairman	Sell	3,784	$499.00	$1,888,216.00	9,994
8/30/2024	Sangeeta N Bhatia	Director	Sell	646	$500.00	$323,000.00	4,435
8/7/2024	Carmen Bozic	CMO	Sell	2,280	$476.75	$1,086,990.00	23,259
8/1/2024	Bruce I. Sachs	Director	Sell	5,295	$508.00	$2,689,860.00	40,000
7/24/2024	Carmen Bozic	CMO	Sell	2,280	$488.46	$1,113,688.80	25,539
7/22/2024	Reshma Kewalramani	CEO	Sell	15,202	$497.00	$7,555,394.00	106,172
7/10/2024	Carmen Bozic	CMO	Sell	2,280	$487.34	$1,111,135.20	27,819
6/26/2024	Carmen Bozic	CMO	Sell	2,280	$471.72	$1,075,521.60	30,099
6/12/2024	Carmen Bozic	CMO	Sell	2,280	$478.00	$1,089,840.00	32,379
6/12/2024	E. Morrey Atkinson, III	EVP	Sell	7,288	$478.00	$3,483,664.00	15,972
5/30/2024	Ourania Tatsis	EVP	Sell	2,350	$439.11	$1,031,908.50	53,523
5/29/2024	Carmen Bozic	CMO	Sell	2,280	$445.56	$1,015,876.80	34,659
5/28/2024	Charles F. Wagner, Jr.	CFO	Sell	3,250	$454.79	$1,478,067.50	50,387
5/24/2024	Reshma Kewalramani	CEO	Sell	1,565	$457.00	$715,205.00	121,374
5/22/2024	Bruce I. Sachs	Director	Sell	7,073	$448.00	$3,168,704.00	40,000
2/26/2024	Ourania Tatsis	EVP	Sell	354	$425.70	$150,697.80	55,804
2/20/2024	Ourania Tatsis	EVP	Sell	480	$420.79	$201,979.20	59,827
2/12/2024	Amit Sachdev	EVP	Sell	3,222	$420.24	$1,354,013.28	74,364
2/12/2024	Jeffrey M. Leiden	Chairman	Sell	2,656	$419.51	$1,114,218.56	27,644
2/12/2024	Kristen Ambrose	CAO	Sell	1,374	$420.24	$577,409.76	9,676
2/12/2024	Stuart A. Arbuckle	COO	Sell	4,295	$420.24	$1,804,930.80	75,718
1/8/2024	Jeffrey M. Leiden	Chairman	Sell	6,648	$419.07	$2,785,977.36	2,423
11/6/2023	Bruce I. Sachs	Director	Sell	11,250	$385.00	$4,331,250.00	40,000
10/31/2023	Carmen Bozic	CMO	Sell	5,651	$355.92	$2,011,303.92	34,952
10/17/2023	Carmen Bozic	CMO	Sell	5,651	$373.25	$2,109,235.75	40,603
10/17/2023	Sangeeta N Bhatia	Director	Sell	243	$375.00	$91,125.00	3,901
10/16/2023	Jeffrey M. Leiden	Chairman	Sell	12,962	$374.00	$4,847,788.00	22,425
10/6/2023	Sangeeta N Bhatia	Director	Sell	242	$360.00	$87,120.00	4,144
10/3/2023	Carmen Bozic	CMO	Sell	5,651	$345.28	$1,951,177.28	46,254
10/2/2023	Jonathan Biller	EVP	Sell	610	$346.76	$211,523.60	10,569
9/19/2023	Carmen Bozic	CMO	Sell	5,651	$351.00	$1,983,501.00	51,905
8/23/2023	Ourania Tatsis	EVP	Sell	2,500	$355.00	$887,500.00	48,637
8/9/2023	David Altshuler	EVP	Sell	63	$345.51	$21,767.13	32,038
8/9/2023	Sangeeta N Bhatia	Director	Sell	242	$345.51	$83,613.42	4,386
7/17/2023	Bruce I. Sachs	Director	Sell	11,250	$356.75	$4,013,437.50	40,000
7/17/2023	Reshma Kewalramani	CEO	Sell	7,828	$355.00	$2,778,940.00	118,906
6/15/2023	Stuart A. Arbuckle	COO	Sell	8,603	$349.00	$3,002,447.00	56,556

SEC Filings (Institutional Ownership Changes) for Vertex Pharmaceuticals (NASDAQ:VRTX)

90.96% of Vertex Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Vertex Pharmaceuticals Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
6/18/2026	Western Wealth Management LLC	1,631	$0.73M	0.0%	+159.7%	0.001%
6/18/2026	Pacer Advisors Inc.	88,863	$39.68M	0.1%	+16.7%	0.035%
6/15/2026	Carmignac Gestion	148,199	$66.16M	1.0%	-22.6%	0.058%
6/9/2026	Rathbones Group PLC	955	$0.43M	0.0%	-23.2%	0.000%
6/8/2026	First National Bank of Mount Dora Trust Investment Services	7,211	$3.22M	0.7%	+16.1%	0.003%
6/3/2026	Parallel Advisors LLC	5,522	$2.47M	0.0%	+6.4%	0.002%
6/3/2026	NewEdge Advisors LLC	17,146	$7.66M	0.0%	-1.1%	0.007%
6/1/2026	Keel Point LLC	947	$0.42M	0.0%	-22.1%	0.000%
5/29/2026	Ramiah Investment Group	969	$0.43M	0.4%	-7.2%	0.000%
5/29/2026	Asset Dedication LLC	237	$0.11M	0.0%	-19.4%	0.000%
5/27/2026	Alpine Woods Capital Investors LLC	716	$0.32M	0.1%	-48.9%	0.000%
5/26/2026	Glenmede Trust Co. NA	5,608	$2.50M	0.0%	+5.0%	0.002%
5/26/2026	Axiom Investment Management LLC	633	$0.28M	0.2%	N/A	0.000%
5/22/2026	Groupama Asset Managment	165,897	$74.08M	1.1%	+1.7%	0.065%
5/22/2026	Segall Bryant & Hamill LLC	38,073	$17M	0.2%	-4.4%	0.015%
5/21/2026	Montchanin Asset Management LLC	6,932	$3.10M	3.1%	N/A	0.003%
5/21/2026	GKV Capital Management Co. Inc.	4,417	$1.97M	0.7%	+2.6%	0.002%
5/21/2026	Vestor Capital LLC	202	$90K	0.0%	+38.4%	0.000%
5/21/2026	BankChampaign National Association	1,374	$0.61M	0.6%	N/A	0.001%
5/20/2026	CCM Investment Advisers LLC	25,894	$11.56M	1.1%	-1.4%	0.010%
5/20/2026	Liontrust Investment Partners LLP	13,691	$6.11M	0.1%	-9.0%	0.005%
5/19/2026	Western Wealth Management LLC	1,631	$0.73M	0.0%	+159.7%	0.001%
5/19/2026	Paragon Private Wealth Management LLC	486	$0.22M	0.1%	+8.0%	0.000%
5/19/2026	Bank of America Corp DE	2,878,183	$1.29B	0.1%	-2.0%	1.134%
5/19/2026	Edgestream Partners L.P.	3,263	$1.46M	0.0%	-51.3%	0.001%
5/19/2026	Kentucky Retirement Systems	19,299	$8.62M	0.3%	+19.5%	0.008%
5/19/2026	Janus Henderson Group PLC	2,131,527	$951.80M	0.5%	-4.1%	0.840%
5/19/2026	Centaurus Financial Inc.	2,721	$1.22M	0.1%	-7.3%	0.001%
5/19/2026	Tri Locum Partners LP	129,314	$57.74M	8.1%	N/A	0.051%
5/19/2026	Oddo BHF Asset Management Sas	10,151	$4.53M	0.2%	-78.2%	0.004%
5/19/2026	Strategic Investment Advisors MI	809	$0.36M	0.0%	-46.5%	0.000%
5/19/2026	Ashton Thomas Securities LLC	3,048	$1.36M	0.2%	+5.0%	0.001%
5/19/2026	Arkadios Wealth Advisors	3,684	$1.65M	0.0%	-7.1%	0.001%
5/19/2026	Smith Group Asset Management LLC	55,746	$24.89M	1.3%	+7.1%	0.022%
5/18/2026	ADAR1 Capital Management LLC	15,075	$6.73M	0.4%	+9.9%	0.006%
5/18/2026	Amundi	1,472,496	$657.53M	0.2%	+12.9%	0.580%
5/18/2026	EverSource Wealth Advisors LLC	1,507	$0.67M	0.0%	+38.1%	0.001%
5/18/2026	California State Teachers Retirement System	373,481	$166.77M	0.2%	-3.2%	0.147%
5/18/2026	Royal Bank of Canada	1,111,871	$496.50M	0.1%	-14.1%	0.438%
5/18/2026	Empowered Funds LLC	41,737	$18.64M	0.1%	+181.9%	0.016%
5/16/2026	Ashford Capital Management Inc.	9,078	$4.05M	0.5%	+10.1%	0.004%
5/16/2026	The Manufacturers Life Insurance Company	553,243	$247.05M	0.2%	-0.8%	0.218%
5/16/2026	KCM Investment Advisors LLC	1,213	$0.54M	0.0%	+24.3%	0.000%
5/16/2026	Glen Eagle Advisors LLC	180	$80K	0.0%	+4,400.0%	0.000%
5/16/2026	Quantinno Capital Management LP	126,604	$56.53M	0.1%	+37.2%	0.050%
5/16/2026	Lazard Asset Management LLC	213,131	$95.17M	0.2%	+7.1%	0.084%
5/15/2026	Gateway Wealth Partners LLC	832	$0.37M	0.0%	N/A	0.000%
5/15/2026	Blue Chip Partners LLC	1,895	$0.85M	0.1%	+12.1%	0.001%
5/15/2026	Quadcap Wealth Management LLC	1,891	$0.84M	0.1%	+5.6%	0.001%
5/15/2026	OMERS ADMINISTRATION Corp	18,797	$8.39M	0.1%	+21.4%	0.007%
5/15/2026	Bradley Foster & Sargent Inc. CT	1,406	$0.63M	0.0%	-2.5%	0.001%
5/15/2026	Lombard Odier Asset Management Switzerland SA	9,312	$4.16M	0.2%	-20.4%	0.004%
5/15/2026	Aristotle Atlantic Partners LLC	37,532	$16.76M	0.8%	-2.2%	0.015%
5/15/2026	Waverly Advisors LLC	23,055	$10.30M	0.1%	+1.4%	0.009%
5/15/2026	Cumberland Partners Ltd	9,376	$4.19M	0.3%	-2.4%	0.004%
5/15/2026	Dempze Nancy E	7,810	$3.49M	1.9%	+10.7%	0.003%
5/15/2026	Sustainable Insight Capital Management LLC	731	$0.33M	0.1%	+37.7%	0.000%
5/15/2026	Bridgewater Advisors Inc.	1,109	$0.50M	0.0%	+3.1%	0.000%
5/15/2026	Cannell & Spears LLC	1,983	$0.89M	0.0%	+1.2%	0.001%
5/14/2026	Healthcare of Ontario Pension Plan Trust Fund	108,251	$48.34M	0.1%	+23.4%	0.043%
5/14/2026	Dai ichi Life Insurance Company Ltd	14,165	$6.33M	0.2%	-2.6%	0.006%
5/14/2026	Renaissance Technologies LLC	421,688	$188.30M	0.3%	-16.5%	0.166%
5/14/2026	Gabelli Funds LLC	7,920	$3.54M	0.0%	-0.8%	0.003%
5/14/2026	Hilltop Holdings Inc.	671	$0.30M	0.0%	-77.7%	0.000%
5/14/2026	GC Wealth Management RIA LLC	1,022	$0.46M	0.0%	-16.4%	0.000%
5/14/2026	Public Employees Retirement System of Ohio	102,985	$45.99M	0.1%	+0.3%	0.041%
5/14/2026	Compound Planning Inc.	6,666	$2.98M	0.1%	+1.9%	0.003%
5/14/2026	Klingman & Associates LLC	529	$0.24M	0.0%	+13.8%	0.000%
5/14/2026	Modern Wealth Management LLC	1,412	$0.63M	0.0%	+10.3%	0.001%
5/14/2026	Arrowstreet Capital Limited Partnership	638,950	$285.32M	0.2%	+7.6%	0.252%
5/14/2026	Caxton Associates LLP	36,026	$16.09M	0.4%	N/A	0.014%
5/14/2026	Bowen Hanes & Co. Inc.	135,399	$60.46M	1.5%	+1.4%	0.053%
5/14/2026	Bank of Nova Scotia	35,361	$15.79M	0.0%	-63.9%	0.014%
5/14/2026	Gibbs Wealth Management	5,647	$2.52M	0.3%	+357.2%	0.002%
5/14/2026	Sei Investments Co.	133,226	$59.49M	0.1%	-63.4%	0.052%
5/14/2026	Keynote Financial Services LLC	1,231	$0.55M	0.3%	+5.6%	0.000%
5/14/2026	MWA Asset Management	4,143	$1.85M	1.0%	+28.8%	0.002%
5/14/2026	Decatur Capital Management Inc.	4,357	$1.95M	0.9%	-1.6%	0.002%
5/13/2026	Cetera Investment Advisers	72,633	$32.43M	0.0%	-3.2%	0.029%
5/13/2026	Alpha Family Trust	1,635	$0.73M	0.4%	+10.1%	0.001%
5/13/2026	Aureus Asset Management LLC	8,395	$3.75M	0.2%	+36.7%	0.003%
5/13/2026	Signature Equity Partners LLC	347	$0.16M	0.1%	+688.6%	0.000%
5/13/2026	NewEdge Wealth LLC	9,788	$4.37M	0.1%	+16.5%	0.004%
5/13/2026	First Citizens Bank & Trust Co.	1,092	$0.49M	0.0%	+20.0%	0.000%
5/13/2026	Alesco Advisors LLC An ESL Co	1,825	$0.82M	0.0%	N/A	0.001%
5/13/2026	CI Investments Inc.	14,000	$6.25M	0.0%	-71.9%	0.006%
5/13/2026	First Trust Advisors LP	306,461	$136.85M	0.1%	+52.2%	0.121%
5/12/2026	Westpac Banking Corp	2,529	$1.13M	0.1%	-2.9%	0.001%
5/12/2026	Meiji Yasuda America Inc	4,159	$1.86M	0.5%	-1.4%	0.002%
5/12/2026	Danica Pension Livsforsikringsaktieselskab	26,126	$11.67M	0.2%	N/A	0.010%
5/12/2026	ABN Amro Investment Solutions	68,216	$30.46M	0.4%	+257.7%	0.027%
5/8/2026	PNC Financial Services Group Inc.	71,942	$32.13M	0.0%	+3.6%	0.028%
5/8/2026	Oslo Pensjonsforsikring AS	657	$0.29M	0.0%	N/A	0.000%
5/8/2026	Baader Bank Aktiengesellschaft	5,280	$2.36M	0.2%	-61.2%	0.002%
5/8/2026	Andra AP fonden	23,903	$10.67M	0.1%	-33.5%	0.009%
5/8/2026	Madison Asset Management LLC	27,387	$12.23M	0.2%	+66.6%	0.011%
5/8/2026	Puzo Michael J	15,414	$6.88M	2.0%	+0.3%	0.006%
5/8/2026	Summit Global Investments	3,896	$1.74M	0.1%	-7.3%	0.002%
5/8/2026	Cassaday & Co Wealth Management LLC	162	$72K	0.0%	N/A	0.000%
5/8/2026	MWA Asset Management	4,147	$1.85M	1.0%	+28.9%	0.002%

Data available starting January 2016

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor. The company's pipeline includes VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1 clinical trial; VX-548, a non-opioid medicine for the treatment of acute and neuropathic pain which is in Phase 3 clinical trial; Exa-cel, for the treatment of sickle cell disease and transfusion-dependent beta thalassemia which is in Phase 2/3 clinical trial. In addition, it provides inaxaplin for the treatment of APOL1-mediated focal segmental glomerulosclerosis and co-morbidities, such as hypertension which is in single Phase 2/3; VX- 880 and VX-264, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-970, which is in Phase 2 clinical trial for the treatment of cancer; and VX-803 and VX-984 for treatment of cancer in Phase 1 clinical trial. Further, it sells the products to specialty pharmacy and specialty distributors in the United States, as well as retail pharmacies, hospitals, and clinics. Additionally, the company has collaborations with CRISPR Therapeutics AG.; Moderna, Inc.; Entrada Therapeutics, Inc.; Arbor Biotechnologies, Inc.; Mammoth Biosciences, Inc.; and Verve Therapeutics., as well as collaborations with Tevard Biosciences to develop novel tRNA-based therapies for duchenne muscular dystrophy. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $451.63

$450.39

$464.98

50 Day Range

MA: $438.56

$423.24

$458.99

52 Week Range

Now: $451.63

$362.50

$507.92

Volume

2,992,667 shs

Average Volume

1,245,948 shs

Market Capitalization

$114.62 billion

P/E Ratio

26.79

Dividend Yield

N/A

Beta

0.3

Who are the company insiders with the largest holdings of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top insider shareholders include:
Jeffrey M Leiden (CEO)
Joshua S Boger (Director)
Joshua Boger (Director)
Joshua S Boger (Director)
Jeffrey M Leiden (CEO)
Jeffrey Leiden (CEO)
Peter Mueller (EVP)
Ian F Smith (CFO)
Stuart A Arbuckle (EVP)
Jeffrey Chodakewitz (CMO)
Learn More about top insider investors at Vertex Pharmaceuticals.
Who are the major institutional investors of Vertex Pharmaceuticals?: Vertex Pharmaceuticals' top institutional investors include:
Bank of America Corp DE — 1.13%
Jennison Associates LLC — 1.08%
Janus Henderson Group PLC — 0.84%
Bank of New York Mellon Corp — 0.62%
Amundi — 0.58%
WCM Investment Management LLC — 0.44%
Learn More about top institutional investors of Vertex Pharmaceuticals stock.
Which major investors are selling Vertex Pharmaceuticals stock?: Within the previous quarter, VRTX stock was sold by these institutional investors:
Jennison Associates LLC
Pictet Asset Management Holding SA
Assenagon Asset Management S.A.
Sei Investments Co.
Manning & Napier Advisors LLC
Royal Bank of Canada
SG Americas Securities LLC
Janus Henderson Group PLC
In the last year, company insiders that have sold Vertex Pharmaceuticals company stock include:
Amit Sachdev (EVP)
Ourania Tatsis (EVP)
Charles F Wagner Jr (EVP)
Carmen Bozic (CMO)
Jeffrey M Leiden (Chairman)
Edward Morrow Atkinson III (EVP)
Joy Liu (EVP)
Jonathan Biller (EVP)
Duncan Mckechnie (EVP)
Mark E Bunnage (EVP)
Kristen Ambrose (CAO)
Sangeeta N Bhatia (Director)
Learn More investors selling Vertex Pharmaceuticals stock.
Which major investors are buying Vertex Pharmaceuticals stock?: During the previous quarter, VRTX stock was acquired by institutional investors including:
Amundi
AMF Tjanstepension AB
SEB Asset Management AB
Tri Locum Partners LP
First Trust Advisors LP
Fifth Third Bancorp
Fjarde AP Fonden Fourth Swedish National Pension Fund
Bank of New York Mellon Corp